Raymond James upgraded shares of Intellia Therapeutics (NASDAQ:NTLA) from a market perform rating to an outperform rating in a report published on Friday, Briefing.com Automated Import reports. The firm currently has $24.00 target price on the stock.
Several other analysts also recently issued reports on NTLA. ValuEngine upgraded Intellia Therapeutics from a hold rating to a buy rating in a report on Wednesday, October 2nd. Zacks Investment Research downgraded Intellia Therapeutics from a buy rating to a hold rating in a research note on Thursday, August 8th. Robert W. Baird assumed coverage on Intellia Therapeutics in a research note on Monday, July 8th. They set an outperform rating and a $23.00 target price for the company. Chardan Capital set a $57.50 target price on Intellia Therapeutics and gave the company a buy rating in a research note on Friday, September 27th. Finally, BidaskClub downgraded Intellia Therapeutics from a sell rating to a strong sell rating in a research note on Friday, October 11th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the stock. Intellia Therapeutics presently has a consensus rating of Buy and an average price target of $25.56.
Shares of NASDAQ NTLA opened at $13.60 on Friday. Intellia Therapeutics has a 12-month low of $10.26 and a 12-month high of $20.38. The company has a market cap of $610.20 million, a P/E ratio of -6.87 and a beta of 2.68. The company has a current ratio of 7.99, a quick ratio of 7.99 and a debt-to-equity ratio of 0.05. The stock has a fifty day moving average price of $12.40 and a 200 day moving average price of $14.99.
A number of large investors have recently bought and sold shares of the stock. Benjamin Edwards Inc. lifted its holdings in Intellia Therapeutics by 60.9% in the second quarter. Benjamin Edwards Inc. now owns 1,691 shares of the company’s stock worth $28,000 after acquiring an additional 640 shares during the last quarter. Bank of Montreal Can lifted its holdings in Intellia Therapeutics by 406.5% in the second quarter. Bank of Montreal Can now owns 3,824 shares of the company’s stock worth $63,000 after acquiring an additional 3,069 shares during the last quarter. Mizuho Securities Co. Ltd. bought a new position in Intellia Therapeutics in the second quarter worth about $64,000. Aperio Group LLC bought a new position in Intellia Therapeutics in the second quarter worth about $83,000. Finally, Resources Investment Advisors LLC. lifted its holdings in Intellia Therapeutics by 60.2% in the second quarter. Resources Investment Advisors LLC. now owns 8,648 shares of the company’s stock worth $142,000 after acquiring an additional 3,250 shares during the last quarter. Institutional investors and hedge funds own 79.38% of the company’s stock.
About Intellia Therapeutics
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, and primary hyperoxaluria.
Read More: Do You Need a Fiduciary?
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.